These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36901822)

  • 21. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
    Martinez-Valbuena I; Amat-Villegas I; Valenti-Azcarate R; Carmona-Abellan MDM; Marcilla I; Tuñon MT; Luquin MR
    Acta Neuropathol; 2018 Jun; 135(6):877-886. PubMed ID: 29536165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
    He Y; Yu Z; Chen S
    ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects.
    Beach TG; Carew J; Serrano G; Adler CH; Shill HA; Sue LI; Sabbagh MN; Akiyama H; Cuenca N;
    Neurosci Lett; 2014 Jun; 571():34-8. PubMed ID: 24785101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. α-Synuclein and dopamine at the crossroads of Parkinson's disease.
    Venda LL; Cragg SJ; Buchman VL; Wade-Martins R
    Trends Neurosci; 2010 Dec; 33(12):559-68. PubMed ID: 20961626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
    Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation.
    Du G; Liu X; Chen X; Song M; Yan Y; Jiao R; Wang CC
    Mol Biol Cell; 2010 Jul; 21(13):2128-37. PubMed ID: 20444973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
    Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
    Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.
    Schulz-Schaeffer WJ
    Acta Neuropathol; 2010 Aug; 120(2):131-43. PubMed ID: 20563819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Contribution of
    Longhena F; Faustini G; Missale C; Pizzi M; Spano P; Bellucci A
    Neural Plast; 2017; 2017():5012129. PubMed ID: 28133550
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Dutta AK; Armstrong C; Luo D; Das B; Spencer B; Rissman RA
    ACS Chem Neurosci; 2023 Mar; 14(5):885-896. PubMed ID: 36749600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Where and how alpha-synuclein pathology spreads in Parkinson's disease.
    Wakabayashi K
    Neuropathology; 2020 Oct; 40(5):415-425. PubMed ID: 32750743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Photoreceptor layer thinning in idiopathic Parkinson's disease.
    Roth NM; Saidha S; Zimmermann H; Brandt AU; Isensee J; Benkhellouf-Rutkowska A; Dornauer M; Kühn AA; Müller T; Calabresi PA; Paul F
    Mov Disord; 2014 Aug; 29(9):1163-70. PubMed ID: 24789530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathomechanisms underlying Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2014 Feb; 14(2):199-215. PubMed ID: 24471711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.